Distribution of TRAP-positive cells and expression of HIF-1a, VEGF, and FGF-2 in the reparative reaction in patients with osteonecrosis of the femoral head

Journal of Orthopaedic Research

Volumn 27, Issue 5, 2009, Pages 694-700

  Li, Weizhe ^a   Sakai, Takashi ^a   Nishii, Takashi ^a   Nakamura, Nobuo ^a   Takao, Masaki ^a   Yoshikawa, Hideki ^a   Sugano, Nobuhiko ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Fibroblast growth factor 2 (FGF 2); Hypoxia inducible factor 1a (HIF 1a); Osteonecrosis; Tartrate resistant acid phosphatase (TRAP); Vascular endothelial growth factor (VEGF)

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN; ACID PHOSPHATASE; ISOENZYME; TARTRATE-RESISTANT ACID PHOSPHATASE; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BONE NECROSIS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEMUR HEAD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRABECULAR BONE; ANGIOGENESIS; BONE DEVELOPMENT; CYTOLOGY; FEMUR HEAD NECROSIS; GENE EXPRESSION; HIP ARTHROPLASTY; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; FEMALE; FEMUR HEAD; FEMUR HEAD NECROSIS; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOENZYMES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65249098265     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20802     Document Type: Article

References (38)

1. Arlet J. 1992. Nontraumatic avascular necrosis of the femoral head: Past, present, and future. Clin Orthop 277:12-21.
2. Mont MA, Hungerford DS. 1995. Current concepts review: Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg 77:459-474.
3. Jones JP Jr. 1991. Etiology and pathogenesis of osteonecrosis. Semin Arthroplasty 2:160-168.
4. Jones LC, Hungerford DS. 2004. Osteonecrosis: etiology, diagnosis, and treatment. Curr Opin Rheumatol 16:443-449.
5. Sissons HA, Nuovo MA, Steiner GC. 1992. Pathology of osteonecrosis of the femoral head. A. review of experience at the Hospital for Joint Diseases, New York. Skeletal Radiol 4:229-238.
6. Plenk H Jr, Gstettner M, Grossschmidt K, et al. 2001. Magnetic Resonance Imaging and histology of repair in femoral head osteonecrosis. Clin Orthop Relat Res 386:42-53.
7. Mont MA, Jones LC, Einhorn TA, et al. 1998. Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Clin Orthop Relat Res 355:314-335.
8. Kim HKW, Randall TS, Bian H, et al. 2005. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am 87:550-557.
9. Kim HKW, Sanders M, Athavale S, et al. 2006. Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infracted femoral head. Bone 39:205-212.
10. Nishii T, Sugano N, Miki H, et al. 2006. Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res 443:273-279.
11. Agarwala S, Jain D, Joshi VR, et al. 2005. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology 44:352-359.
12. Lai KA, Shen WJ, Yang CY, et al. 2005. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. J Bone Joint Surg Am 87:2155-2159.
13. Trueta J. 1963. The role of the vessels in osteogenesis. J Bone Joint Surg Br 45:402-418.
14. Carano RA, Filvaroff EH. 2003. Angiogenesis and bone repair. Drug Discov Today 8:980-989.
15. Kim HH, Lee SE, Chung WJ, et al. 2002. Stabilization of hypoxia-inducible factor-1alpha is involved in the hypoxic stimuli-induced expression of vascular endothelial growth factor in osteoblastic cells. Cytokine 17:14-27.
16. Street J, Bao M, deGuzman L, et al. 2002. Vascular endothelial growth factor stimulates bone repair bypromoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 15:9656-9661.
17. Nakamae A, Sunagawa T, Ishida O, et al. 2004. Acceleration of surgical angiogenesis in necrotic bone with a single injection of fibroblast growth factor-2 (FGF-2). J Orthop Res 22:509-513.
18. Hong JM, Kim TH, Chae SC, et al. 2007. Association study of hypoxia inducible factor 1alpha (HIF1alpha) with osteonec- rosis of femoral head in a Korean population. Osteoarthritis Cartilage 15:688-694.
19. Radke S, Battmann A, Jatzke S, et al. 2006. Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteovecrosis of the femoral head. J Othop Res 24:945-952.
20. Gardeniers JWM. 1993. ARCO Committee on Terminology and Staging. ARCO Newslett 5:79-82.
21. Sugano N, Atsumi T, Ohzono K, et al. 2002. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J Orthop Sci 7:601-605.
22. Sternberger LA, Sternberger NH. 1986. The unlabeled antibody method: comparison of peroxidase-antiperoxidase with avidin-biotin complex by a new method of quantification. J Histochem Cytochem 5:599-605.
23. Starklint H, Lausten GS, Arnoldi CC. 1995. Microvascular obstruction in avascular necrosis: Immunohistochemistry of 14 femoral heads. Acta Orthop Scand 66:9-12.
24. Trueta J, Harrison MHM. 1953. The normal vascular anatomy of the femoral head in adult man. J Bone Joint Surg Am 35:442-461.
25. Astrand J, Aspenberg P. 2002. Systemic alendronate prevents resorption of necrotic bone during revascularization. A. bone chamber study in rats. BMC Musculoskelet Disord 3:19.
26. Hofstaetter J, Wang J, Samuel R, et al. 2005. The effect of alendronate in the treatment of experimental osteonecrosis. Trans Orthop Res Soc 30:318.
27. Calvani M, Rapisarda A, Uranchimeg B, et al. 2006. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107:2705-2717.
28. Egger M, Schgoer W, Beer AG, et al. 2007. Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF- 1a and basic FGF-dependent pathway in muscle cells. FASEB J 21:2906-2923.
29. Wiener CM, Bocth G, Semenza GL. 1996. In vivo expression of mRNAs encoding hypoxia inducible factor. Biochem Biophys Res 225:485-488.
30. Dai Y, Xu M, Wang Y, et al. 2007. HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardio- myocytes against ischemia. J Mol Cell Cardiol 42:1036-1044.
31. Peng H, Wright V, Usas A, et al. 2002. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110:751-759.
32. Gerber HP, Vu TH, Ryan AM, et al. 1999. VEGF couples hypertrophic cartilage remodeling, ossification and angiogesis during endochondral bone formation. Nat Med 6:623-628.
33. Haigh JJ, Gerber HP, Ferrara N, et al. 2000. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 7:1445-1453.
34. Boyce BF, Hughes DE, Wright KR, et al. 1999. Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab Invest 79:83-94.
35. Goldfarb M. 1996. Functions of fibroblast growth factors in vertebrate development. Cytokine Growth Factor Rev 7:311-325.
36. Marie P, Debiais F, Cohen-Solal M, et al. 2000. New factors controlling bone remodeling. Joint Bone Spine 67:150-156.
37. Collin-Osdoby P, Rothe L, Bekker S, et al. 2002. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J Bone Miner Res 17:1859-1871.
38. Warren SM, Brunet LJ, Harland RM, et al. 2003. The BMP antagonist noggin regulates cranial suture fusion. Nature 422:625-629.